The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Daiichi Sankyo; Dedham Group; Defined Health; DLA Piper; Eisai; Eisai; Elephas Bio; Exelixis; GU Oncology Now; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Nimbus Therapeutics; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Scholar Rock; SignifyMD; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Kurt Demel
No Relationships to Disclose
 
Marcus Noel
Consulting or Advisory Role - Celgene; Ipsen; Merus; Moderna Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - Celgene; Daiichi Sankyo/Astra Zeneca; Taiho Pharmaceutical
Research Funding - ERYTECH Pharma
 
Hamid Emamekhoo
Consulting or Advisory Role - Bristol Myers Squibb company; Cardinal Health; Cardinal Health; Eisai; Janssen Biotech
 
Julio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen
Consulting or Advisory Role - Exigent Research Network
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Rama Balaraman
Honoraria - Cardinal Health
Consulting or Advisory Role - Bristol Myers Squibb and AstraZeneca
Research Funding - Bristol Myers Squibb Foundation
 
Ryan Moy
Consulting or Advisory Role - Bristol Myers Squibb; IDEAYA Biosciences; Nimbus Therapeutics; PureTech
Research Funding - Nimbus Therapeutics; Repare Therapeutics
Travel, Accommodations, Expenses - Nimbus Therapeutics
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics
Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Arif Hussain
No Relationships to Disclose
 
Joanna Haas
Employment - Nimbus Therapeutics
 
Daria Chabas
Employment - Nimbus Therapeutics
 
Sue Dasen
Employment - Nimbus Therapeutics
 
Xinyan Zhang
Employment - Nimbus Therapeutics
Stock and Other Ownership Interests - Equity Quotient
 
Scott Daigle
Employment - Nimbus Therapeutics
Stock and Other Ownership Interests - Equity Quotient
 
Ginell Elliott
Employment - Nimbus Therapeutics
Stock and Other Ownership Interests - Equity Quotient
 
Sritama Nath
Employment - Nimbus Therapeutics
Stock and Other Ownership Interests - Equity Quotient
 
Pavan Kumar
Employment - Nimbus Therapeutics
Stock and Other Ownership Interests - Equity Quotient
 
Anita Scheuber
Employment - Nimbus Therapeutics
 
David Sommerhalder
Employment - Texas Oncology
Stock and Other Ownership Interests - Next Oncology; Texas Oncology/US Oncology
Honoraria - Syneos Health
Consulting or Advisory Role - Nimbus Therapeutics; Revolution Medicines
Research Funding - Abbvie (Inst); Acrivon Therapeutics (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); Biomea Fusion (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Day One Biopharmaceuticals (Inst); Dicerna (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Haihe Pharmaceutical (Inst); IconOVir Bio (Inst); Immuneering (Inst); IMPAC Medical Systems (Inst); Incendia Pharmaceuticals AB (Inst); Kura Oncology (Inst); MediLink (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Monopteros Therapeutics (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); Nimbus Therapeutics (Inst); Novo Nordisk (Inst); OBI Pharma (Inst); OncoResponse (Inst); Pfizer (Inst); Revolution Medicines (Inst); Step Pharma (Inst); Symphogen (Inst); Tachyon Therapeutics (Inst); Teon Therapeutics (Inst); Tyligand Bioscience (Inst); Vincera Pharma/Vincerx Pharma (Inst); Vividion Therapeutics (Inst); ZielBio (Inst); Zymeworks (Inst)